Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Shares Dive on Lowered FY2008 Revenue Forecast

This article has been updated to include information on Affymetrix's stock movement.
 
NEW YORK (GenomeWeb News) – Shares of Affymetrix tumbled 36.5 percent to a new 52-week low in early Tuesday trade after the firm disclosed late yesterday afternoon that it expects its full-year 2008 revenue to be approximately 3 percent lower than the amount it previously forecast.
 
The Santa Clara, Calif.-based microarray firm lowered its revenue projection to a range of between $490 million and $510 million from its previous guidance of between $505 million and $525 million, which it made during its fourth-quarter 2007 conference call in January.
 
Investors fled the stock overnight and this morning, pushing the firm's shares down $5.96 to $10.37 in Nasdaq trading.
 
“This reduction in revenue expectations for the full year is primarily the result of expected lower research spending by pharmaceutical and industrial customers,” Affymetrix said in yesterday's statement. “The company is currently reviewing ways to further reduce operating expenses to offset the impact of this revenue reduction.”
 
Affymetrix also said that it expects first-quarter revenue to be roughly $170 million, which includes a $90 million payment from Illumina to settle litigation between the firms. Analysts had predicted the firm would report revenue of around $182.5 million, including the payment.
 
Affymetrix disclosed in a filing with the US Securities and Exchange Commission at the end of February that it would move the “majority” of its probe array manufacturing from its West Sacramento, Calif., facility to its Singapore facility by the end of 2008 as part of an ongoing effort to reduce costs.
 
The firm will release its first-quarter results after the close of the market on April 24.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.